Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Information source: Mantecorp Industria Quimica e Farmaceutica Ltd.
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis
Intervention: 0.5% prednisolone acetate cream (Drug); 0.1% betamethasone valerate cream (Drug)
Phase: Phase 3
Status: Not yet recruiting
Sponsored by: Mantecorp Industria Quimica e Farmaceutica Ltd.
Official(s) and/or principal investigator(s):
Mário C Pires, MD, Principal Investigator, Affiliation: Hospital Padre Bento de Guarulhos
Roberta F. J. Criado, MD, Principal Investigator, Affiliation: Faculdade d Medicina do ABC
Adilson Costa, MD, Principal Investigator, Affiliation: KOLderma
Cláudia Domingues, Phone: 55115188.5237, Email: firstname.lastname@example.org
Topical corticosteroids are largely used in dermatology. The major problem related to their
use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and
antiproliferative) may lead to adverse events. Conditions sensitive to corticosteroids
require formulations with mild to moderate potency while high-potency corticosteroids era
required in less responsive conditions. The aim of the present study is to compare the
safety and efficacy of prednisolone acetate 0. 5% cream (mild-potency non-fluoridated
corticosteroid) versus betamethasone valerate 0. 1% cream (high-potency fluoridated
corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic
dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). The study hypothesis
is that 0. 5% prednisolone cream will be as effective as 0. 1% betamethasone cream and will be
an alternative option to treat corticosensitive dermatosis in body areas where the use of
fluoridated corticosteroids is contraindicated, such as the face.
Official title: Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Evaluate efficacy and safety of 0.5% prednisolone cream in comparison to 0.1% betamethasone cream in the treatment of corticosensitive dermatosis.
Secondary outcome: Evaluate physicians' and patients' perception of the efficacy and tolerability of treatment.
Minimum age: 12 Years.
Maximum age: 60 Years.
- Subjects with corticosensitive dermatosis (atopic dermatitis, contact dermatitis,
seborrheic dermatitis, psoriasis) mild to moderate in intensity;
- Compliance of the subject to the treatment protocol;
- Agreement with the terms o the informed consent by the participants
- Subjects who did not use the following medicines before inclusion: topical
corticosteroids or other therapies to dermatitis (30 days); oral corticosteroids (180
days); parenteral corticosteroids (180 days); immunomodulators/immunosuppressor (30
days); any drug under investigation (1 year); any therapy for the studied clinical
conditions (180 days); keratolytic agents (30 days); emollient agents (30 days);
tazarotene (30 days); vitamin D (topical or oral, 30 days); methotrexate (30 days);
acitretin (2 years); UV light (30 days); PUVA therapy (30 days).
- Pregnancy or risk of pregnancy
- History of allergy of any component of the formulations
- Other conditions considered by the investigator as reasonable for non-eligibility
- HIV positivity
- Drug abuse
- Subjects without previous response to topical corticosteroids
- Subjects with intense sun exposure within 15 days of the screening
Locations and Contacts
Cláudia Domingues, Phone: 55115188.5237, Email: email@example.comAdditional Information
Starting date: February 2010
Last updated: November 10, 2009